Drug interaction label changes for URL's Colcrys
This article was originally published in Scrip
URL Pharmaceuticals has updated the label of Colcrys (colchicine), its treatment for gout and familial Mediterranean fever (FMF), to reduce the dosing recommendations for patients who are taking HIV protease inhibitors that are boosted by low-dose ritonavir.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.